Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase I study of the preventive effect of Kampo medicine on oxaliplatin-induced peripheral neurotoxicity

ABSTRACT: Interventions: During XELOX regimen, Kampo medicine is administered as follows: Level 1(TJ-18 7.5g, TJ-3023 0g), Level 2(TJ-18 7.5g, TJ-3023 1.5g), Level 3(TJ-18 7.5g, TJ-3023 3.0g) Primary outcome(s): Decision of DLT, MTD, RD of Kampo medicine (TJ-3023, TJ-18) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631410 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Preventive effect of Bushimatsu and Keishikajubutou on peripheral neurotoxicity of Oxaliplatin(L-OHP) therapy: a phase II clinical study.

Project description:Interventions: administration of keishi kajutubu tou (TJ - 18) + Bushi matsu (TJ - 3023) Primary outcome(s): Safety and efficacy of Keishi Kamisukutou (TJ - 18) + bushi-matsu (TJ - 3023) for oxaliplatin-induced peripheral neuropathy Study Design: Single arm Non-randomized

| 2646318 | ecrin-mdr-crc

Preventive effect of Bushimatsu and Keishikajutsubuto on peripheral neurotoxicity of Oxaliplatin(L-OHP) therapy: a phase II clinical study.

Project description:Interventions: Administration of Keishikajutsubuto (TJ - 18) + Bushi matsu (TJ - 3023) Primary outcome(s): dose limiting toxicity, maximum tolerated dose, recommended Dose Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615226 | ecrin-mdr-crc

Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy :A Placebo-controlled Double-blind Randomized Phase III Study

Project description:Interventions: Goshajinkigan 7.5g/day, 12 course + mFOLFOX6 12 course Placebo 7.5g/day, 12 course + mFOLFOX6 12 course Primary outcome(s): TimeToGrade2+ (CTCAE v4.0) Neuropathy; TTN Study Design: Parallel Randomized

| 2619732 | ecrin-mdr-crc

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606621 | ENA

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606620 | ENA

Expression data of 8 healthy people and 8 patients with coronary heart disease before and after 8 weeks treatment with Danlou tablets

Project description:The Danlou Tablets (DLT), a patented medicine, has been widely used to treat coronary heart disease (CHD) in China for several decades. Though the anti-inflammatory and anti-oxidation effect has been preliminarily proposed as one of the potential mechanisms of DLT for CHD treatment, the underlying mechanisms remain elusive. We use microarray to explain the genome changes of patients with coronary heart disease and patients with coronary heart disease after treatment with Danlou tablets, so as to explore the potential mechanism of treating diseases with traditional Chinese medicine.

2023-06-14 | GSE179789 | GEO

medicine metagenome

Project description:medicine metagenome Raw sequence reads

| PRJNA903771 | ENA

medicine metagenome

Project description:medicine metagenome Raw sequence reads

| PRJNA884878 | ENA

A Japanese herbal medicine, Hochuekkito (TJ-41), has anti-inflammatory effects on the COPD mouse model

Project description:We assessed the anti-inflammatory and systemic effects of TJ-41 on the COPD mouse model induced by porcine pancreatic elastase (PPE) and lipopolysaccharide (LPS).

2024-05-15 | GSE239537 | GEO

traditional chinese medicine

Project description:traditional chinese medicine Targeted loci

| PRJNA796441 | ENA